Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 under

the Securities Exchange Act of 1934

For the month of July 2021

Commission File Number 001-39670

 

 

PURETECH HEALTH PLC

 

 

6 Tide Street, Suite 400

Boston, Massachusetts 02210

Attention: Chief Executive Officer

[phone]

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

---

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On July 19, 2021, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) issued a press release announcing that its founded entity, Gelesis, plans to become a publicly traded company via a merger with Capstar Special Purpose Acquisition Corp. The press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

---

Exhibits

 

99.1		Press Release dated July  19, 2021, “PureTech Founded Entity Gelesis, the Maker of Plenity®, to Become a Publicly Traded Company via Merger with Capstar Special Purpose Acquisition Corp.”

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

				PURETECH HEALTH PLC
Date: July 19, 2021				By:		/s/ Daphne Zohar
						Name:		Daphne Zohar
						Title:		Chief Executive Officer